Kamada Ltd（KMDA）のニュースとイベントKMDAKamada Ltd

Kamada Launches Two Biosimilars in Israel

Kamada announced the expansion of its biosimilar portfolio with the commercial launch of two additional new products in Israel, adding to its existing portfolio of two products. The two newly launched biosimilar products are Ustekinumab-Kamada, a biosimilar to Stelara, a monoclonal antibody indicated for the treatment of chronic immune-mediated inflammatory diseases, including plaque psoriasis, psoriatic arthritis, Crohn's disease and ulcerative colitis, and Enoxaparin-Kamada, a biosimilar to Clexane, a low-molecular-weight heparin indicated for the prevention and treatment of thromboembolic disorders, including deep vein thrombosis and pulmonary embolism, as well as for use in certain acute coronary syndrome settings. The launch of the new products is in addition to the company's first two biosimilar products, Bevacizumab-Kamada, a biosimilar to Avastin, and Pegfilgrastim-Kamada, a biosimilar to Neulasta, which were launched in the Israeli market over the last two years. The company expects the commercial availability of at least two additional biosimilar products during 2027. All four biosimilar products were approved and launched as interchangeable with the reference original biologic product. Kamada's existing commercial portfolio of biosimilars is anticipated to generate approximately $4M in sales in 2026, growing to approximately $10M in 2028. By 2030, the company expects this strategic portfolio to include at least 12 marketed products, licensed from 6 different leading international biosimilar companies, to be commercialized in Israel and the Middle East and North Africa region, with the expectation to generate between approximately $20M to $25M in annual revenue. Kamada expects that additional biosimilar products, licensed by Kamada, will be in development or registration phase by 2030, contributing to further meaningful expansion of the portfolio.

Kamada Confirms Sufficient KedRAB Supply for Increased U.S. Demand

Kamada confirmed that it maintains sufficient KedRAB supply and manufacturing capacity to meet increased demand for the product in the United States. The confirmation follows a Health Advisory published by the U.S. Centers for Disease Control and Prevention on September 10, reporting a significant nationwide year-over-year increase in human rabies exposures and the use of rabies post-exposure prophylaxis. In light of this increase in end-user utilization described in the CDC advisory, Kamada confirms it has the inventory and manufacturing capacity to support the continued supply of KedRAB, a human rabies immune globulin developed and manufactured by Kamada, which is one of only two FDA-approved anti-rabies immunoglobulin products indicated for PEP treatment in the U.S. The product is supplied to the U.S. market via the Company's U.S. commercialization partner, Kedrion Biopharma.

Kamada Files to Sell $50M of Ordinary Shares

Kamada files to sell $50M of ordinary shares